M. Scot Roberts - Jun 27, 2022 Form 4 Insider Report for Altimmune, Inc. (ALT)

Role
Chief Scientific Officer
Signature
/s/ Kent A. Tapper, as Attorney-in-Fact
Stock symbol
ALT
Transactions as of
Jun 27, 2022
Transactions value $
-$368,502
Form type
4
Date filed
6/28/2022, 07:00 PM
Previous filing
Feb 3, 2022
Next filing
Jun 30, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALT Common Stock, par value $0.0001 Options Exercise $49.2K +25.6K +144.54% $1.92 43.3K Jun 27, 2022 Direct
transaction ALT Common Stock, par value $0.0001 Options Exercise $30.6K +11.8K +27.19% $2.60 55.1K Jun 27, 2022 Direct
transaction ALT Common Stock, par value $0.0001 Sale -$448K -37.4K -67.85% $12.00 17.7K Jun 27, 2022 Direct F1, F2
holding ALT Common Stock, par value $0.0001 15 Jun 27, 2022 Shares held by spouse of Reporting Person

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALT Stock Options (option to buy) Options Exercise $0 -25.6K -41.67% $0.00 35.8K Jun 27, 2022 Common Stock, par value $0.0001 61.4K $1.92 Direct F3
transaction ALT Stock Options (option to buy) Options Exercise $0 -11.8K -39.23% $0.00 18.2K Jun 27, 2022 Common Stock, par value $0.0001 30K $2.60 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.0000 to $12.0250, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 Twenty-five percent of the shares underlying the option become vested and exercisable on January 2, 2021 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 2, 2021, subject to the reporting person's continued service through the applicable vesting date.
F4 Twenty-five percent of the shares underlying the option become vested and exercisable on the first anniversary of the Grant Date and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following the one-year anniversary of the Grant Date, in each case, generally subject to the reporting person's continued service through the applicable vesting date.

Remarks:

Exhibit 24 - Power of Attorney